Close
CDMO Safety Testing 2026
Novotech

Velesco Pharma set for clinical manufacturing capacity expansion

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...
- Advertisement -

Pharmaceutical development and clinical manufacturing expert, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharmaโ€™s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the companyโ€™s existing manufacturing site in Kalamazoo, MI.

As part of the expansion, the company has continued toย  invest in its growing team ย with the recent promotion of two senior leaders. Peter Angus has moved into the role of Vice President of Research while Lisa Crandall is now Vice President of Development. Both have been with Velesco Pharma since its inception.

Founded in 2007, Velesco Pharma supports early and later stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.

Dave Barnes, Velesco Pharmaโ€™s CEO: โ€œThis investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects.

โ€œOur team forged their careers in big pharma R&D and bring a wealth of expertise to the table. This experience combined with our personalized and agile approach makes us an ideal choice for clients in the critical early and later stage drug development phases.

โ€œAs a business we have always placed great emphasis on adding scientific value to the drug development process and this continues to be central to our ethos as we expand and move forward.โ€

The new facility is set to be fully operational by the end of this year.

For more information on Velesco Pharma visit ย http://www.velescopharma.com

About Velesco Pharmaceutical Services

Velesco Pharma was formed by former big pharma R&D colleagues and focuses on supporting early and later stage drug development. Velesco provides fast and cost-effective contract analytical development and drug formulation services along with cGMP clinical supplies offering a full range of non-sterile dosage forms. The team offers personalized project management, state-of-the-art facilities and an experienced laboratory staff leading to comprehensive research relationships.

Latest stories

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป